Creative Planning purchased a new stake in Cryolife Inc (NYSE:CRY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,906 shares of the medical equipment provider’s stock, valued at approximately $243,000.
Several other hedge funds and other institutional investors have also made changes to their positions in CRY. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Cryolife by 117.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,305 shares of the medical equipment provider’s stock worth $176,000 after purchasing an additional 3,400 shares during the period. United Services Automobile Association purchased a new position in Cryolife during the second quarter worth approximately $208,000. NewFocus Financial Group LLC purchased a new position in Cryolife during the second quarter worth approximately $218,000. Piedmont Investment Advisors LLC purchased a new position in Cryolife during the second quarter worth approximately $220,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Cryolife in the second quarter worth $278,000. 71.08% of the stock is currently owned by institutional investors.
Several research firms have recently issued reports on CRY. Northland Securities reissued a “buy” rating and issued a $32.00 price objective on shares of Cryolife in a research report on Tuesday, August 7th. Zacks Investment Research raised shares of Cryolife from a “hold” rating to a “strong-buy” rating and set a $36.00 price objective for the company in a research report on Monday, November 5th. Finally, Canaccord Genuity increased their price objective on shares of Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th.
Cryolife (NYSE:CRY) last released its quarterly earnings results on Wednesday, October 31st. The medical equipment provider reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.01. The business had revenue of $64.60 million during the quarter, compared to analyst estimates of $64.57 million. Cryolife had a negative net margin of 2.05% and a positive return on equity of 4.25%. The business’s revenue was up 46.8% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. On average, analysts forecast that Cryolife Inc will post 0.33 earnings per share for the current fiscal year.
In other Cryolife news, VP John E. Davis sold 3,333 shares of the firm’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $33.86, for a total transaction of $112,855.38. Following the completion of the transaction, the vice president now directly owns 52,564 shares of the company’s stock, valued at approximately $1,779,817.04. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director C Elkins Ronald sold 5,000 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $34.53, for a total transaction of $172,650.00. The disclosure for this sale can be found here. 3.97% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2018/12/03/creative-planning-invests-243000-in-cryolife-inc-cry-stock.html.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Recommended Story: Is a Roth IRA right for you?
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.